Anti-il-6 antibodies for the treatment of oral mucositis

Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.

1 .- 481 . (canceled) 
     
     
         482 . A method of treatment or prevention of graft versus host disease (GVHD) in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702. 
     
     
         483 . A method of treatment or prevention of transplant rejection in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702. 
     
     
         484 . A method of treatment or prevention of reperfusion injury in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702.